{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:47:37Z","timestamp":1791308857020,"version":"4.3.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.coi.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T17:41:01Z","timestamp":1303494061000},"page":"377-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":188,"title":["Viral vectors as vaccine platforms: deployment in sight"],"prefix":"10.1016","volume":"23","author":[{"given":"Christine S","family":"Rollier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Reyes-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G","family":"Cottingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian VS","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2011.03.006_bib0005_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2011.03.006_bib0010_1","first-page":"86","article-title":"Gene-based vaccines: recent developments","volume":"12","author":"Liu","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.coi.2011.03.006_bib0015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1128\/jvi.70.3.1651-1667.1996","article-title":"Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G, The WHO and NIAID Networks for HIV Isolation and Characterization","volume":"70","author":"Gao","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2011.03.006_bib0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/MB:29:3:255","article-title":"Overview of vaccines and vaccination","volume":"29","author":"Ada","year":"2005","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.coi.2011.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1126\/science.1192517","article-title":"Induction of broadly neutralizing H1N1 influenza antibodies by vaccination","volume":"329","author":"Wei","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.coi.2011.03.006_bib0030","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"Letourneau","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2011.03.006_bib0035","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/eji.201040344","article-title":"Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques","volume":"40","author":"Rosario","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2011.03.006_bib0040","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nm.2108","article-title":"Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys","volume":"16","author":"Santra","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2011.03.006_bib0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.2089","article-title":"Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys","volume":"16","author":"Barouch","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2011.03.006_bib0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/mp060098+","article-title":"Vaccine delivery methods using viral vectors","volume":"4","author":"Brave","year":"2007","journal-title":"Mol Pharm"},{"key":"10.1016\/j.coi.2011.03.006_bib0055_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2011.03.006_bib0060_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1128\/IAI.00740-09","article-title":"Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses","volume":"78","author":"Reyes-Sandoval","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2011.03.006_bib0065","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.4049\/jimmunol.1002751","article-title":"Robust vaccine-elicited cellular immune responses in breast milk following systemic Simian Immunodeficiency Virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys","volume":"185","author":"Wilks","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2011.03.006_bib0070","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2011.03.006_bib0075","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1128\/JVI.02533-09","article-title":"Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant","volume":"84","author":"Barnett","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2011.03.006_bib0080","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1128\/JVI.02563-09","article-title":"Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes","volume":"84","author":"Kaufman","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2011.03.006_bib0085","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coi.2011.03.006_bib0090","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","article-title":"Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy","volume":"27","author":"Dudareva","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2011.03.006_bib0095","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/eji.200839130","article-title":"Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection","volume":"39","author":"Soloff","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2011.03.006_bib0100","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1016\/j.vaccine.2010.06.050","article-title":"Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28","volume":"28","author":"Kahl","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2011.03.006_bib0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2008.11.003","article-title":"A preliminary and comparative evaluation of a novel Ad5 [E1- E2b-] recombinant-based vaccine used to induce cell mediated immune responses","volume":"122","author":"Gabitzsch","year":"2009","journal-title":"Immunol Lett"},{"key":"10.1016\/j.coi.2011.03.006_bib0110","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1128\/JVI.01840-09","article-title":"Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection","volume":"84","author":"Bayer","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2011.03.006_bib0115","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1128\/JVI.77.17.9553-9566.2003","article-title":"Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods","volume":"77","author":"Rux","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2011.03.006_bib0120","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/JVI.76.6.2667-2675.2002","article-title":"Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product","volume":"76","author":"Xiang","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2011.03.006_bib0125","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4049\/jimmunol.170.3.1416","article-title":"A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag","volume":"170","author":"Fitzgerald","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2011.03.006_bib0130","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1128\/JVI.78.14.7392-7399.2004","article-title":"Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes","volume":"78","author":"Reyes-Sandoval","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2011.03.006_bib0135","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/eji.200737672","article-title":"Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei","volume":"38","author":"Reyes-Sandoval","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2011.03.006_bib0140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.vaccine.2010.10.041","article-title":"Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates","volume":"29","author":"Capone","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2011.03.006_bib0145","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2011.03.006_bib0150","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2011.03.006_bib0155_1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2011.03.006_bib0160","doi-asserted-by":"crossref","first-page":"e9015","DOI":"10.1371\/journal.pone.0009015","article-title":"Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses","volume":"5","author":"Koup","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2011.03.006_bib0165","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1086\/650299","article-title":"A phase 1\/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)","volume":"201","author":"Kibuuka","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2011.03.006_bib0170","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/655468","article-title":"AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein","volume":"202","author":"Schooley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2011.03.006_bib0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10875-009-9275-y","article-title":"CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy","volume":"29","author":"Killian","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coi.2011.03.006_bib0180","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1371\/journal.pone.0001052","article-title":"Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials","volume":"2","author":"Pathan","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2011.03.006_bib0185","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.4049\/jimmunol.1001760","article-title":"Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines","volume":"185","author":"Draper","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2011.03.006_bib0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine","volume":"8","author":"Kennedy","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2011.03.006_bib0195","doi-asserted-by":"crossref","first-page":"e1638","DOI":"10.1371\/journal.pone.0001638","article-title":"Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)","volume":"3","author":"Cottingham","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2011.03.006_bib0200_1","doi-asserted-by":"crossref","first-page":"19ra12","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci Transl Med"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791511000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791511000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:25:05Z","timestamp":1760603105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791511000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0952791511000318"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2011.03.006","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral vectors as vaccine platforms: deployment in sight","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2011.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}